Why smarter cold chains are needed to improve global health standards

By Admin
A new generation of cold chains needs to be developed for the life sciences and health care industry, according to a new report by DHL Global Forwarding...

A new generation of cold chains needs to be developed for the life sciences and health care industry, according to a new report by DHL Global Forwarding.

Product integrity and security throughout the supply chain remains to be the highest priority for health care manufacturers, but stricter regulations, extended geographic coverage and intense cost pressure are now raising the stakes.

RELATED TOPIC: TOP 10: Myths about hospital inventory management debunked

Pharmaceuticals are expensive and sensitive, and product integrity is paramount as ultimately someone’s health and even life may depend upon it.

With global demand, particularly in emerging markets, growing hand in hand with even stricter compliance from regulators, the industry faces a critical situation unless a new generation of cold chains are developed that can support growth aspirations and at the same time safeguard products.

 “Astounding developments in the life sciences industry coupled with globalization means there is an opportunity for better health, pain relief and cure from disease for many millions of people around the world,” said Frank Appel, CEO of Deutsche Post DHL Group. “But getting the medication to patients in the right condition and achieving that goal requires a complex balancing of cost and risk. It emphasizes yet again the strong link between trade, logistics and the impact it has on improving people´s lives.”

RELATED TOPIC: 4 ways to transform the European medical device supply chain

According to our sister brand Supply Chain Digital, global spending on health care is forecasted to reach around $1.3 trillion by 2018 and the World Economic Forum estimates that by 2020 one third of all global health expenditure will be in emerging markets.

Specialty drugs and biologics are one of the fastest growth areas, with U.S. spending on specialty drugs to quadruple to $401.7 billion in 5 years, according to PricewaterhouseCoopers, with similar growth rates being projected for the rest of the world.

“Collapsed cold chains due to non-appropriate conditions can result in loss of a shipment worth hundreds of thousands of dollars. Over the longer term, this can lead to a damaged reputation, slumping sales, potential share value and even pose a risk to patients. These are high stakes and a smarter supply chain is necessary to overcome these challenges.

RELATED TOPIC: How NHS SBS is transforming health care procurement

“As the life sciences and health care industry expands and transforms to meet the growing needs of the world, logistics providers need specialist investment in research and development as well to be able to offer the expertise needed to get medicine and equipment to the patients. In the simplest terms: better logistics can contribute to better health care,” said Angelos Orfanos, President Life Sciences & Healthcare, DHL Customer Solutions & Innovation.

The full report can be downloaded here.

Let's connect!   

Read the latest edition of Healthcare Global magazine!

Share

Featured Articles

The Merck Group: Pharma's History & Innovation in India

Welcome back to part two of our exploration of The Merck Group's history and investment in China and India, with this part focusing on innovation in India

How CVS Health is Rising to the Omnichannel Challenge

US healthcare company CVS Health is reshaping its supply chain to meet the omnichannel needs of its customers

Kinaxis: Pharma Seeing Euro-wide Supply Chain Challenges

Supply chain specialist Kinaxis says UK pharma still recovering from Brexit and pandemic, and that Europe also seeing medicines value chain problems

Healthcare Digital Transformations Stymied by Data Silos

Digital Healthcare

McKinsey: Brain Health Underfunding 'a Global Concern'

Digital Healthcare

Endometriosis Linked to Heart Attacks & Strokes

Medical Devices & Pharma